Amneal Pharmaceuticals Inc (AMRX)
7.8150  -0.1050 (-1.33%)

Amneal Pharmaceuticals is a leading pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company offers a broad portfolio of high-quality, cost-effective medications across various therapeutic areas, including central nervous system disorders, infectious diseases, and pain management. Amneal is committed to improving access to essential medications through innovation in drug formulation and delivery. With a robust pipeline of products and a dedication to regulatory compliance, Amneal aims to meet the diverse needs of patients and healthcare providers while contributing to the overall efficiency of the healthcare system.

SummaryNewsPress ReleasesChartHistorical
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecastsbenzinga.com
Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth.
Via Benzinga · November 8, 2024
Earnings Outlook For Amneal Pharmaceuticalsbenzinga.com
Via Benzinga · November 7, 2024
What's Next: Amneal Pharmaceuticals's Earnings Previewbenzinga.com
Via Benzinga · November 7, 2024
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stabilitybenzinga.com
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Via Benzinga · September 6, 2024
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024investorplace.com
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 9, 2024
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeksinvestorplace.com
Here are three stocks to buy up 100% in the past year. Make sure you add these to your portfolio so that you can reap the benefits.
Via InvestorPlace · June 25, 2024